Slide 1: Third Quarter 2021 Financial Results & Business Update
Third Quarter 2021 Financial Results & Business Update October 27, 2021 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the co
Slide 3: Agenda
Agenda Introduction Sandy Coombs, SVP, Corporate Affairs & Investor Relations Welcome Richard Pops, Chief Executive Officer Q3 2021 Financial Results Iain Brown, Chief Financial Officer Q3 2021 Commercial Review Todd Nichols, Chief Commercial Officer Q3 2021 R&D Update Craig Hopkinson, Chief Medical
Slide 4: Q3 2021 Financial Results Summary
Q3 2021 Financial Results Summary In millions In millions In millions
Slide 5: Q3 2021 Revenue Summary
Q3 2021 Revenue Summary * Inclusive of ARISTADA INITIO® Amounts in the table above do not sum due to rounding.
Slide 6: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations Q3’21 year-over-year net sales increased 11% to $88.8M, driven by unit growth of 7.5% Gross-to-net deductions: 52.3% in Q3’21, compared to 52.8% in Q3’20 Inventory levels increased sequentially by ~$1.5M in line with increasing demand trends and typical seasona
Slide 7: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations Q3’21 year-over-year net sales increased 10% to $68.9M, driven by unit growth of 10% Gross-to-net deductions: 54.8% in Q3’21, compared to 53.7% in Q3’20 Inventory levels decreased by ~$1M in Q3’21 following ~$6M increase in inventory levels in Q2’21 FY’21 net s
Slide 8: ARISTADA: Prescription Growth Trends
ARISTADA®: Prescription Growth Trends Q3’21 year-over-year growth of 15% on TRx months of therapy (MOT) basis Outpaced overall atypical long-acting injectable (LAI) market Q3’21 year-over-year growth of 6% Market share: TRx MOT: 9.8% of atypical LAI market prescriptions in Q3’21 ARISTADA Quarterly T
Slide 9: Strong Commercial and Operational Execution
Strong Commercial and Operational Execution Commercial Execution Drove solid VIVITROL® and ARISTADA® year-over-year growth Commenced launch of LYBALVI®, which became commercially available in October Nemvaleukin Alfa (“nemvaleukin”) Granted U.S. Food and Drug Administration (FDA) Fast Track designat
Slide 10: Alkermes: 2021 Financial Expectations
Alkermes: 2021 Financial Expectations* * These expectations were initially provided by the Company in its Form 8-K filed with the SEC on July 28, 2021. These expectations are reiterated by the Company in its Form 8-K filed with the SEC on Oct. 27, 2021 and are effective only as of such date. The Com
Slide 11: www.alkermes.com
www.alkermes.com